General

Home>News>General

Cartherics to present at the 2023 BIO International Convention

Melbourne, Australia, 24 May 2023 – Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it is presenting at the upcoming 2023 BIO International Convention June 5-8, 2023, in Boston, Massachusetts. CEO Prof. Alan Trounson will meet with senior biotech executives, business development leaders […]

2023-09-06T10:30:15+10:00May 24th, 2023|

Cartherics congratulates Rasa Islam on PhD success

Cartherics is delighted to announce that Rasa Islam has successfully completed her PhD candidature.

Rasa’s research thesis, titled, Re-engineering the function of natural killer cell receptors via CRISPR/Cas9: a new approach for ‘off the shelf’ immunotherapy, investigated the generation of Natural Killer (NK) cells (immune cells) from gene-edited stem cells to provide an ‘off-the-shelf’ supply for […]

2023-05-24T13:38:44+10:00May 16th, 2023|

Cartherics to present at the CIMT Annual Meeting in Germany

Cartherics is pleased to announce that PhD Candidate, Van To, will be presenting at the Association for Cancer Immunotherapy’s 20th CIMT Annual Meeting in Germany.

CIMT is Europe’s largest meeting focused on cancer immunotherapy research and development. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As […]

2023-05-24T13:39:14+10:00May 2nd, 2023|

Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China

Melbourne, Australia, 28 April 2023 –  Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has granted Shunxi Holding Group Co Ltd (“Shunxi”) a licence to develop, manufacture and commercialise Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumours including […]

2023-04-28T13:00:59+10:00April 28th, 2023|

Cartherics to present at ThymOz 2023

Cartherics will be presenting at the ThymOZ 2023 International Conference on T Cells to be held from 22 -26 March at Heron Island in Queensland, Australia. The conference covers a broad range of topics including T cell differentiation and function, stromal cell biology, immunotherapy and tissue regeneration.

Rachelle Duffin, PhD Candidate at Cartherics will be presenting […]

2023-03-22T09:32:06+11:00March 22nd, 2023|

Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Ovarian Cancer

Melbourne, Victoria, Australia 27 February 2023

Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer.

The clinical trial to be conducted by Peter Mac will be the first […]

2023-02-27T14:37:49+11:00February 27th, 2023|

Cartherics is ‘Turning Teal’ this February in support of ovarian cancer

Cartherics is delighted to be hosting a Teal Tea this February to raise awareness and funds for people affected by ovarian cancer.

Ovarian Cancer Australia’s Teal Ribbon Day is an initiative that aims to start conversations that change lives. It will increase awareness of the disease and help raise funds to support people affected by […]

2023-05-24T13:40:58+10:00February 22nd, 2023|

Cartherics celebrates PhD student’s success

Cartherics is delighted to announce that Saleh Almasabi has successfully completed his PhD Candidature.

Saleh’s research thesis, The role of integrin linked kinase in senescence and immunosuppressive tumor microenvironment in colon cancer’, identified that integrin-linked kinase (ILK) is associated with cancer prognosis and characterises the immunosuppressive tumor microenvironment. These findings suggest possible clinical avenues of targeting […]

2023-02-06T13:37:22+11:00February 6th, 2023|

CGTLive Interview: New Frontiers in Allogeneic Cell Therapy

Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours.

Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ovarian, […]

2023-02-01T11:57:58+11:00January 20th, 2023|

Cartherics granted first patent in China for multiple development candidates

Melbourne, Australia, 09 January 2023Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This patent is part of the family represented by the international patent filing WO2017088012.

The […]

2023-01-09T14:10:25+11:00January 9th, 2023|
Go to Top